(Q35597612)

9 August 2017

title

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

A Erhardt

1 reference

9 August 2017

D Blondin

1 reference

9 August 2017

K Hauck

1 reference

9 August 2017

A Sagir

1 reference

9 August 2017

T Kohnle

1 reference

9 August 2017

T Heintges

1 reference

9 August 2017

D Häussinger

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

1009-1013

1 reference

Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Hepatitis B virus infection--natural history and clinical consequences

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Viral features of lamivudine resistant hepatitis B genotypes A and D.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Hepatitis B virus genotypes: comparison of genotyping methods

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Genetic variability in hepatitis B viruses

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Management of hepatitis B: 2000--summary of a workshop

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Classification of chronic hepatitis: diagnosis, grading and staging

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774609

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B

26 September 2018

1 reference

12 December 2020

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

12 December 2020

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

12 December 2020

The molecular basis of hepatitis B e antigen (HBeAg)-negative infections

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

12 December 2020

Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B

1 reference

12 December 2020

Hepatitis B genotypes and the response to interferon therapy

1 reference

12 December 2020

Identifiers

DOI

10.1136/GUT.2004.060327

1 reference

9 August 2017

1 reference

9 August 2017

1 reference